Compare VERA & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VERA | TMDX |
|---|---|---|
| Founded | 2016 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.6B |
| IPO Year | 2021 | 2019 |
| Metric | VERA | TMDX |
|---|---|---|
| Price | $32.24 | $82.70 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 9 |
| Target Price | $81.30 | ★ $148.22 |
| AVG Volume (30 Days) | ★ 2.2M | 641.5K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 382.18 |
| EPS | N/A | ★ 0.61 |
| Revenue | N/A | ★ $605,494,000.00 |
| Revenue This Year | N/A | $24.25 |
| Revenue Next Year | $472.48 | $18.75 |
| P/E Ratio | ★ N/A | $135.62 |
| Revenue Growth | N/A | ★ 37.13 |
| 52 Week Low | $23.05 | $60.11 |
| 52 Week High | $56.05 | $156.00 |
| Indicator | VERA | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 43.46 | 43.73 |
| Support Level | $30.05 | $80.29 |
| Resistance Level | $33.09 | $90.67 |
| Average True Range (ATR) | 2.15 | 3.96 |
| MACD | -0.24 | -0.63 |
| Stochastic Oscillator | 13.70 | 31.29 |
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.